Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cubist Acquires Illumigen Biosciences

January 7, 2008 | A version of this story appeared in Volume 86, Issue 1
Advertisement

Most Popular in Business

Cubist Pharmaceuticals has acquired Illumigen Biosciences, which specializes in the use of human genetic mutations in drug discovery and development. Illumigen's lead compound, IB657, is in preclinical development for the treatment of hepatitis C virus (HCV) infection. Under the deal, Cubist will pay $9 million to establish Illumigen as a subsidiary and will pay Illumigen's former owners up to $75.5 million upon reaching regulatory milestones. Cubist could pay up to $117 million for the development of products that treat viruses other than HCV. Cubist CEO Mike Bonney says the firm hopes to make an investigational new drug filing for IB657 and begin clinical trials this year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society

You might also like...

Alexion to acquire autoimmune drug firm Syntimmune for up to $1.2 billion
BMS Gets Rights To Promedior Drug
Novartis Takes All Of Ofatumumab

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE